Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1Phase 2/3 1Phase 2 1

Status

Unknown 1Recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Dermatologic 2Lymphoid 1

Conditions

Skin Neoplasms 1Melanoma 1

Interventions

pembrolizumab 81Nivolumab 55Ipilimumab 44Cyclophosphamide 38aldesleukin 26Interleukin-2 25fludarabine 17Temozolomide 17fludarabine phosphate 16trametinib 11dabrafenib 11Radiotherapy 11Biopsy 11avelumab 10Paclitaxel 9spartalizumab 8cemiplimab 8Dacarbazine 8Cisplatin 8Bevacizumab 8sargramostim 7binimetinib 7Fluorouracil 7poly ICLC 6lenvatinib 6epacadostat 6atezolizumab 6Magnetic Resonance Spectroscopy 6Granulocyte-Macrophage Colony-Stimulating Factor 6montanide ISA 51 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × peginterferon alfa-2a × Dermatologic × Clear all
NCT07288112 2026-04-14

DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma

Diakonos Oncology Corporation

Phase 1/2 Recruiting
35 enrolled
Dermatologic

Melanoma

NCT00423397 2013-12-19

Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer

National Cancer Institute (NCI)

Phase 1/2 Unknown
16 enrolled
Dermatologic

Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡